Sterkers Nicolas, Chabrol Jean L, De Troyer Jeremy, Bonijol Dany, Darmon Jean C, Donnez Olivier
1 Gynecologic Department, Urbain V Clinic, Avignon, France.
2 Anesthesia Department, Urbain V Clinic, Avignon, France.
J Vasc Access. 2018 Jul;19(4):382-386. doi: 10.1177/1129729818757975. Epub 2018 Mar 23.
Recent reviews support that hypnosis has great potential for reducing pain and anxiety during mini-invasive surgery. Here, we assessed the feasibility of hypnotic induction session as adjunct therapy in conscious sedation for venous access device implantation. Primary outcomes were safety and patient satisfaction.
Thirty consecutive women with breast cancer were proposed adjunct of hypnosis before implantation under conscious sedation (midazolam: 0.5 mg ± bolus of Ketamin: 5 mg on demand) indicated for chemotherapy. Self-hypnosis was programmed and guided by one of two trained anesthesiologists. Implantation was performed by one of two experimented surgeons. It consisted of blind subclavian implantation of Braun ST 305 devices using a percutaneous technique adapted from Selinger's procedure. Clinical data were prospectively collected and retrospectively analyzed. A comprehensive custom-made questionnaire recorded patient satisfaction.
In all, 30/30 patients consented to the procedure. The median age was 54 years (range: 35-77 years). The primary procedure was successful in 29/30. One case was converted into internal jugular vein access after a first attempt. Median length time of the implantation procedure in the operative room was 20 min (range: 10-60 min). Median length time in the recovery room preceding home discharge was 65 min (range: 15-185 min). None of the patients suffered complications. The satisfaction rate was ≥90%, 27/30 patients would get hypnosis in case of reimplantation if necessary and 27/30 would recommend this procedure to others.
Hypnosis under conscious sedation appears feasible and safe for port implantation under conscious sedation in cancer patients. Further studies would determine the exact value of hypnosis effectiveness.
近期综述表明,催眠在微创手术中减轻疼痛和焦虑方面具有巨大潜力。在此,我们评估了催眠诱导环节作为辅助治疗用于静脉通路装置植入清醒镇静的可行性。主要结局指标为安全性和患者满意度。
连续30例乳腺癌女性患者在植入静脉通路装置前接受催眠辅助清醒镇静(咪达唑仑:0.5mg±按需追加氯胺酮:5mg),用于化疗。自我催眠由两名经过培训的麻醉医生之一进行编程和指导。植入手术由两名经验丰富的外科医生之一进行。手术采用经皮技术,在盲视下将贝朗ST 305装置植入锁骨下静脉,该技术改编自塞林格氏法。前瞻性收集临床数据并进行回顾性分析。通过一份综合定制问卷记录患者满意度。
30例患者全部同意接受该手术。中位年龄为54岁(范围:35 - 77岁)。30例中有29例首次手术成功。1例首次尝试后改为颈内静脉置管。手术室植入手术的中位时长为20分钟(范围:10 - 60分钟)。出院前在恢复室的中位时长为65分钟(范围:15 - 185分钟)。无一例患者出现并发症。满意度≥90%,27/30例患者表示如有必要再次植入愿意接受催眠,27/30例患者会向他人推荐该手术。
清醒镇静下的催眠用于癌症患者清醒镇静下的端口植入似乎可行且安全。进一步研究将确定催眠有效性的确切价值。